Edwards Lifesciences Corporatio vs Merck & Company, Inc. — Stock Comparison
Edwards Lifesciences Corporatio (EW) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Edwards Lifesciences Corporatio scores ahead of Merck & Company, Inc. on Q·Score (7 vs 6 out of 10), led by Quality (6.7 vs 4.4) and Health (9.2 vs 7). Merck & Company, Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for EW (+10.7%) than for MRK (+6.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ earnings contracting 25% year-over-year.
68% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
EW vs MRK: which stock scores better overall?
Based on Q·Score, Edwards Lifesciences Corporatio (EW) scores 7/10 versus Merck & Company, Inc. (MRK) at 6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: EW or MRK?
Edwards Lifesciences Corporatio (EW) scores higher on Growth (5.2/10 vs 5.1/10). Edwards Lifesciences Corporatio reports revenue growth (13.6% YoY) while Merck & Company, Inc. reports (4.7% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is EW or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (7/10 vs 6.3/10). EW trades at 27.2× P/E versus MRK at 16.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about EW vs MRK?
There are 27 analysts covering EW with a consensus price target of $101.87, and 26 analysts covering MRK with a consensus target of $159.60. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: EW or MRK?
Edwards Lifesciences Corporatio (EW) scores higher on Quality (6.7/10 vs 4.4/10). Net profit margin: EW at 15.4%, MRK at 3.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: EW or MRK?
Edwards Lifesciences Corporatio (EW) scores higher on Financial Health (9.2/10 vs 7/10). Market beta: EW at 0.86, MRK at N/A. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of EW and MRK?
Edwards Lifesciences Corporatio (EW) has a market capitalisation of $53.0B, while Merck & Company, Inc. (MRK) has a market cap of $368.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do EW or MRK pay dividends?
EW does not currently pay a dividend, while MRK pays a dividend yield of 2.32%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →